UPDATE: Danaher's Life Science and Dx Sales Inch up 1 Percent in Q1 | GenomeWeb

The story has been updated to include commments from Danaher's conference call.

NEW YORK (GenomeWeb News) – Danaher today reported that its sales in the first quarter increased 3 percent year over year, while sales in the Life Science and Diagnostics segment inched up 1 percent.

The company recorded companywide sales of $4.44 billion, up from $4.32 billion in the first quarter of 2012, but short of the average Wall Street estimate of $4.50 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.